HSA-/PLGA-nanoparticles as diagnostic markers for hepatocellular carcinoma (HCC)
Hepatocellular carcinoma (HCC) is one of the most common malignant tumors. For curative treatment options, early diagnosis is crucial. In this context, the present invention provides a new contrast agent, made of Gd-DTPA-loaded HSA-/PLGA-nanoparticles for magnetic resonance imaging (MRI) enabling the detection of small HCC which are undetectable with current methods and improving differentiation between HCC and benign lesions in the cirrhotic lever.
Further Information: PDF
INNOVECTIS Gesellschaft für Innovations-Dienstleistungen mbH
Phone: +49 (0)69/2561632-0
Contact
Dr. Otmar Schöller
Media Contact
All latest news from the category: Technology Offerings
Newest articles
Why getting in touch with our ‘gerbil brain’ could help machines listen better
Macquarie University researchers have debunked a 75-year-old theory about how humans determine where sounds are coming from, and it could unlock the secret to creating a next generation of more…
Attosecond core-level spectroscopy reveals real-time molecular dynamics
Chemical reactions are complex mechanisms. Many different dynamical processes are involved, affecting both the electrons and the nucleus of the present atoms. Very often the strongly coupled electron and nuclear…
Free-forming organelles help plants adapt to climate change
Scientists uncover how plants “see” shades of light, temperature. Plants’ ability to sense light and temperature, and their ability to adapt to climate change, hinges on free-forming structures in their…
